Video
Author(s):
Focusing on clinical trials and novel therapies, Rami Komrokji, MD, and Ruben Mesa, MD, share their hope for the future management of essential thrombocythemia and polycythemia vera.
Stay up to date on cancer updates, research and education
Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis
P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia